Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure

Circulation Journal

Volumn 76, Issue 1, 2012, Pages 117-126

  Susa, Takehisa ^a   Kobayashi, Shigeki ^a   Tanaka, Takeo ^a   Murakami, Wakako ^a   Akashi, Shintaro ^a   Kunitsugu, Ichiro ^b   Okuda, Shinichi ^a   Doi, Masahiro ^a   Wada, Yasuaki ^a   Nao, Tomoko ^a   Yamada, Jutaro ^a   Ueyama, Takeshi ^a   Okamura, Takayuki ^a   Yano, Masafumi ^a   Matsuzaki, Masunori ^a  

^a Department of Medicine and Clinical Science ^*  (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Heart failure; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOOP DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATIENT CODING; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SIDE EFFECT; SYSTOLIC HEART FAILURE; TREATMENT RESPONSE; URINE LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BIOLOGICAL MARKERS; CARBAZOLES; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; DEOXYGUANOSINE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROPANOLAMINES; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84255189682     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0537     Document Type: Article

References (39)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
2. Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005; 111: 2637-2649.
3. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-1283.
4. Mentz RJ, Felker GM. Natriuretic peptide-guided therapy for heart failure. Circ J 2011; 75: 2031-2037.
5. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin- 6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-1593.
6. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L; CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
7. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20: 1799-1807.
8. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinosita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
9. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
10. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, et al; National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation 2007; 116: e95-e98.
11. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
12. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-2116.
13. Iwanaga Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers: An integrated viewpoint. Circ J 2010; 74: 1274-1282.
14. Zimmet JM, Hare JM. Nitroso-redox interaction in the cardiovascular system. Circulation 2006; 114: 1531-1544.
15. Bergamini C, Cicoira M, Rossi A, Vassanelli V. Oxidative stress and hyperuricaemia: Pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009; 11: 444-452.
16. Banfi C, Brioschi M, Barcella S, Veglia F, Biglioli P, Tremoli E, et al. Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage. Eur J Heart Fail 2008; 10: 244-251.
17. Eleuteri E, Magno F, Gnemmi I, Carbone M, Colombo M, La Rocca G, et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci 2009; 14: 2230-2237.
18. Ungvári Z, Gupte SA, Recchia FA, Bátkai S, Pacher P. Role of oxidative- nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005; 3: 221-229.
19. Tang WHW, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007; 49: 2364-2370.
20. Wolfram R, Oguogho A, Palumbo B, Sinzinger H. Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha). Eur J Heart Fail 2005; 7: 167-172.
21. Polidori MC, Praticó D, Savino K, Rokach J, Stahl W, Mecocci P. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 2004; 10: 334-338.
22. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 2003; 24: 2180-2185.
23. Radovanovic S, Krotin M, Simic DV, Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, et al. Markers of oxidative damage in chronic heart failure: Role in disease progression. Redox Rep 2008; 13: 109-116.
24. Kaneko T, Tahara S, Matsuo M. Non-linear accumulation of 8- hydroxy-2'-deoxyguanosine, a marker of oxidized DNA damage, during aging. Mutat Res 1996; 316: 277-285.
25. Ames BN. Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun 1989; 7: 121-128.
26. Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: Influence of smoking, gender and body mass index. Carcinogenesis 1992; 13: 2241-2247.
27. Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001; 88: 529-535.
28. Tsutsui H, Ide T, Shiomi T, Kang D, Hayashidani S, Suematsu N, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2001; 104: 2883-2885.
29. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K, et al. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J 2006; 70: 1001-1005.
30. Kobayashi S, Susa T, Tanaka T, Wada Y, Okuda S, Doi M, et al. Urinary 8-hydroxy-2'-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 29-36.
31. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-842.
32. Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H, et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 2000; 85: 81-85.
33. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Tadashi H, Tokumoto M, et al. Locally activated rennin-angiotensin system associated with TGF-β1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2003; 11: 616-624.
34. 2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 2007; 49: 1722-1732.
35. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-2871.
36. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 2086-2092.
37. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-388.
38. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure: Special reference to transcardiac [corrected] gradient of norepinephrine. Circ J 2009; 73: 2270-2275.
39. Konishi M, Haraguchi G, Kimura S, Inagaki H, Kawabata M, Hachiya H, et al. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. Circ J 2010; 74: 1127-1134.